Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI).

Circulation

Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, Muehlhofer E, Widimsky P, Yusuf S, Eikelboom JW, Bhatt DL.
PMID: 32178526
Circulation. 2020 Apr 07;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17.

BACKGROUND: The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major...

Cite
Bainey KR, Welsh RC, Connolly SJ, et al. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020;141(14):1141-1151doi: 10.1161/CIRCULATIONAHA.119.044598.
Bainey, K. R., Welsh, R. C., Connolly, S. J., Marsden, T., Bosch, J., Fox, K. A. A., Steg, P. G., Vinereanu, D., Connolly, D. L., Berkowitz, S. D., Foody, J. M., Probstfield, J. L., Branch, K. R., Lewis, B. S., Diaz, R., Muehlhofer, E., Widimsky, P., Yusuf, S., Eikelboom, J. W., Bhatt, D. L. (2020). Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation, 141(14), 1141-1151. https://doi.org/10.1161/CIRCULATIONAHA.119.044598
Bainey, Kevin R, et al. "Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)." Circulation vol. 141,14 (2020): 1141-1151. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.044598
Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, Muehlhofer E, Widimsky P, Yusuf S, Eikelboom JW, Bhatt DL. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020 Apr 07;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17. PMID: 32178526.
Copy Download .nbib Format: NLM
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Heart (British Cardiac Society)

Dagenais GR, Dyal L, Bosch JJ, Leong DP, Aboyans V, Berkowitz SD, Bhatt DL, Connolly SJ, Fox KAA, Muehlhofer E, Probstfield JL, Widimsky P, Winkelmann BR, Yusuf S, Eikelboom JW.
PMID: 34021038
Heart. 2021 Jul;107(14):1130-1137. doi: 10.1136/heartjnl-2020-318758. Epub 2021 May 21.

OBJECTIVE: In patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months because of benefits of the combination...

Cite
Dagenais GR, Dyal L, Bosch JJ, et al. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021;107(14):1130-1137doi: 10.1136/heartjnl-2020-318758.
Dagenais, G. R., Dyal, L., Bosch, J. J., Leong, D. P., Aboyans, V., Berkowitz, S. D., Bhatt, D. L., Connolly, S. J., Fox, K. A. A., Muehlhofer, E., Probstfield, J. L., Widimsky, P., Winkelmann, B. R., Yusuf, S., & Eikelboom, J. W. (2021). Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart (British Cardiac Society), 107(14), 1130-1137. https://doi.org/10.1136/heartjnl-2020-318758
Dagenais, Gilles R, et al. "Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease." Heart (British Cardiac Society) vol. 107,14 (2021): 1130-1137. doi: https://doi.org/10.1136/heartjnl-2020-318758
Dagenais GR, Dyal L, Bosch JJ, Leong DP, Aboyans V, Berkowitz SD, Bhatt DL, Connolly SJ, Fox KAA, Muehlhofer E, Probstfield JL, Widimsky P, Winkelmann BR, Yusuf S, Eikelboom JW. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021 Jul;107(14):1130-1137. doi: 10.1136/heartjnl-2020-318758. Epub 2021 May 21. PMID: 34021038; PMCID: PMC8257559.
Copy Download .nbib Format: NLM
Garlic tablets are ineffective in hypercholesterolemia.

Evidence-based cardiovascular medicine

Probstfield JL.
PMID: 16379853
Evid Based Cardiovasc Med. 1998 Dec;2(4):103. doi: 10.1016/s1361-2611(98)80042-0.

No abstract available.

Cite
Probstfield JL. Garlic tablets are ineffective in hypercholesterolemia. Evid Based Cardiovasc Med. 1998;2(4):103doi: 10.1016/s1361-2611(98)80042-0.
Probstfield, J. L. (1998). Garlic tablets are ineffective in hypercholesterolemia. Evidence-based cardiovascular medicine, 2(4), 103. https://doi.org/10.1016/s1361-2611(98)80042-0
Probstfield, J L. "Garlic tablets are ineffective in hypercholesterolemia." Evidence-based cardiovascular medicine vol. 2,4 (1998): 103. doi: https://doi.org/10.1016/s1361-2611(98)80042-0
Probstfield JL. Garlic tablets are ineffective in hypercholesterolemia. Evid Based Cardiovasc Med. 1998 Dec;2(4):103. doi: 10.1016/s1361-2611(98)80042-0. PMID: 16379853.
Copy Download .nbib Format: NLM
Observed Changes in Risk during Naturopathic Treatment of Hypertension.

Evidence-based complementary and alternative medicine : eCAM

Bradley R, Kozura E, Kaltunas J, Oberg EB, Probstfield J, Fitzpatrick AL.
PMID: 21799695
Evid Based Complement Alternat Med. 2011;2011:826751. doi: 10.1093/ecam/nep219. Epub 2011 Mar 13.

Few outcome assessments are published from complementary and alternative medicine (CAM) practices. We aimed to describe patient and practice characteristics of ND care for hypertension (HTN), quantify changes in blood pressure (BP), and evaluate the proportion achieving control of...

Cite
Bradley R, Kozura E, Kaltunas J, et al. Observed Changes in Risk during Naturopathic Treatment of Hypertension. Evid Based Complement Alternat Med. 2011;2011:826751doi: 10.1093/ecam/nep219.
Bradley, R., Kozura, E., Kaltunas, J., Oberg, E. B., Probstfield, J., & Fitzpatrick, A. L. (2011). Observed Changes in Risk during Naturopathic Treatment of Hypertension. Evidence-based complementary and alternative medicine : eCAM, 2011826751. https://doi.org/10.1093/ecam/nep219
Bradley, Ryan, et al. "Observed Changes in Risk during Naturopathic Treatment of Hypertension." Evidence-based complementary and alternative medicine : eCAM vol. 2011 (2011): 826751. doi: https://doi.org/10.1093/ecam/nep219
Bradley R, Kozura E, Kaltunas J, Oberg EB, Probstfield J, Fitzpatrick AL. Observed Changes in Risk during Naturopathic Treatment of Hypertension. Evid Based Complement Alternat Med. 2011;2011:826751. doi: 10.1093/ecam/nep219. Epub 2011 Mar 13. PMID: 21799695; PMCID: PMC3137652.
Copy Download .nbib Format: NLM
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.

Circulation

Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanas F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S.
PMID: 33906372
Circulation. 2021 Jun;143(22):2129-2142. doi: 10.1161/CIRCULATIONAHA.120.050850. Epub 2021 Apr 28.

BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there are few data on HRQL in HF and the association between HRQL and mortality outside Western countries.METHODS: We used the Kansas City Cardiomyopathy Questionnaire-12...

Cite
Johansson I, Joseph P, Balasubramanian K, et al. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation. 2021;143(22):2129-2142doi: 10.1161/CIRCULATIONAHA.120.050850.
Johansson, I., Joseph, P., Balasubramanian, K., McMurray, J. J. V., Lund, L. H., Ezekowitz, J. A., Kamath, D., Alhabib, K., Bayes-Genis, A., Budaj, A., Dans, A. L. L., Dzudie, A., Probstfield, J. L., Fox, K. A. A., Karaye, K. M., Makubi, A., Fukakusa, B., Teo, K., Temizhan, A., Wittlinger, T., Maggioni, A. P., Lanas, F., Lopez-Jaramillo, P., Silva-Cardoso, J., Sliwa, K., Dokainish, H., Grinvalds, A., McCready, T., Yusuf, S. (2021). Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 143(22), 2129-2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850
Johansson, Isabelle, et al. "Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries." Circulation vol. 143,22 (2021): 2129-2142. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050850
Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanas F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation. 2021 Jun;143(22):2129-2142. doi: 10.1161/CIRCULATIONAHA.120.050850. Epub 2021 Apr 28. PMID: 33906372.
Copy Download .nbib Format: NLM
Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial.

Diabetes, obesity & metabolism

Raubenheimer PJ, Cushman WC, Avezum A, Basile J, Conget I, Dagenais G, Hoover A, Jansky P, Lanas F, Leiter LA, Lopez-Jaramillo P, Pogosova N, Probstfield J, Rao-Melacini P, Rydén L, Sheu WH, Temelkova-Kurktschiev T, Gerstein H.
PMID: 34984808
Diabetes Obes Metab. 2022 Jan 04; doi: 10.1111/dom.14634. Epub 2022 Jan 04.

AIMS: Diabetes mellitus is an independent risk factor for atrial fibrillation or atrial flutter (atrial arrythmia, AA). Additionally, some diabetes medications may influence AA incidence. The aim of this post hoc analysis was to assess the occurrence of AA...

Cite
Raubenheimer PJ, Cushman WC, Avezum A, et al. Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial. Diabetes Obes Metab. 2022;doi: 10.1111/dom.14634.
Raubenheimer, P. J., Cushman, W. C., Avezum, A., Basile, J., Conget, I., Dagenais, G., Hoover, A., Jansky, P., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Pogosova, N., Probstfield, J., Rao-Melacini, P., Rydén, L., Sheu, W. H., Temelkova-Kurktschiev, T., & Gerstein, H. (2022). Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial. Diabetes, obesity & metabolism, . https://doi.org/10.1111/dom.14634
Raubenheimer, Peter J, et al. "Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial." Diabetes, obesity & metabolism vol. (2022). doi: https://doi.org/10.1111/dom.14634
Raubenheimer PJ, Cushman WC, Avezum A, Basile J, Conget I, Dagenais G, Hoover A, Jansky P, Lanas F, Leiter LA, Lopez-Jaramillo P, Pogosova N, Probstfield J, Rao-Melacini P, Rydén L, Sheu WH, Temelkova-Kurktschiev T, Gerstein H. Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial. Diabetes Obes Metab. 2022 Jan 04; doi: 10.1111/dom.14634. Epub 2022 Jan 04. PMID: 34984808.
Copy Download .nbib Format: NLM
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.

Circulation

Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanas F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S.
PMID: 33906372
Circulation. 2021 Jun;143(22):2129-2142. doi: 10.1161/CIRCULATIONAHA.120.050850. Epub 2021 Apr 28.

BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there are few data on HRQL in HF and the association between HRQL and mortality outside Western countries.METHODS: We used the Kansas City Cardiomyopathy Questionnaire-12...

Cite
Johansson I, Joseph P, Balasubramanian K, et al. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation. 2021;143(22):2129-2142doi: 10.1161/CIRCULATIONAHA.120.050850.
Johansson, I., Joseph, P., Balasubramanian, K., McMurray, J. J. V., Lund, L. H., Ezekowitz, J. A., Kamath, D., Alhabib, K., Bayes-Genis, A., Budaj, A., Dans, A. L. L., Dzudie, A., Probstfield, J. L., Fox, K. A. A., Karaye, K. M., Makubi, A., Fukakusa, B., Teo, K., Temizhan, A., Wittlinger, T., Maggioni, A. P., Lanas, F., Lopez-Jaramillo, P., Silva-Cardoso, J., Sliwa, K., Dokainish, H., Grinvalds, A., McCready, T., Yusuf, S. (2021). Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 143(22), 2129-2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850
Johansson, Isabelle, et al. "Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries." Circulation vol. 143,22 (2021): 2129-2142. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050850
Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanas F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation. 2021 Jun;143(22):2129-2142. doi: 10.1161/CIRCULATIONAHA.120.050850. Epub 2021 Apr 28. PMID: 33906372.
Copy Download .nbib Format: NLM
Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial.

Data in brief

O'Brien KD, Hippe DS, Chen H, Neradilek MB, Probstfield JL, Peck S, Isquith DA, Canton G, Yuan C, Polissar NL, Zhao XQ, Kerwin WS.
PMID: 26977429
Data Brief. 2016 Jan 02;6:476-81. doi: 10.1016/j.dib.2015.12.030. eCollection 2016 Mar.

This brief data article summarizes the clinical risk factors and laboratory data of a group of subjects recruited for the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) and an...

Cite
O'Brien KD, Hippe DS, Chen H, et al. Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. Data Brief. 2016;6:476-81doi: 10.1016/j.dib.2015.12.030.
O'Brien, K. D., Hippe, D. S., Chen, H., Neradilek, M. B., Probstfield, J. L., Peck, S., Isquith, D. A., Canton, G., Yuan, C., Polissar, N. L., Zhao, X. Q., & Kerwin, W. S. (2016). Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. Data in brief, 6476-81. https://doi.org/10.1016/j.dib.2015.12.030
O'Brien, Kevin D, et al. "Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial." Data in brief vol. 6 (2016): 476-81. doi: https://doi.org/10.1016/j.dib.2015.12.030
O'Brien KD, Hippe DS, Chen H, Neradilek MB, Probstfield JL, Peck S, Isquith DA, Canton G, Yuan C, Polissar NL, Zhao XQ, Kerwin WS. Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. Data Brief. 2016 Jan 02;6:476-81. doi: 10.1016/j.dib.2015.12.030. eCollection 2016 Mar. PMID: 26977429; PMCID: PMC4773570.
Copy Download .nbib Format: NLM
Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis.

Evidence-based cardiovascular medicine

Probstfield JL.
PMID: 16379772
Evid Based Cardiovasc Med. 1998 Mar;2(1):7. doi: 10.1016/s1361-2611(98)80005-5.

No abstract available.

Cite
Probstfield JL. Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis. Evid Based Cardiovasc Med. 1998;2(1):7doi: 10.1016/s1361-2611(98)80005-5.
Probstfield, J. L. (1998). Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis. Evidence-based cardiovascular medicine, 2(1), 7. https://doi.org/10.1016/s1361-2611(98)80005-5
Probstfield, J L. "Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis." Evidence-based cardiovascular medicine vol. 2,1 (1998): 7. doi: https://doi.org/10.1016/s1361-2611(98)80005-5
Probstfield JL. Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis. Evid Based Cardiovasc Med. 1998 Mar;2(1):7. doi: 10.1016/s1361-2611(98)80005-5. PMID: 16379772.
Copy Download .nbib Format: NLM
Evaluating research mentors working in the area of clinical translational science: a review of the literature.

Clinical and translational science

Meagher E, Taylor L, Probsfield J, Fleming M.
PMID: 22029808
Clin Transl Sci. 2011 Oct;4(5):353-8. doi: 10.1111/j.1752-8062.2011.00317.x.

The goal of this paper is to review the evaluation of mentors with a focus on training new investigators in clinical translational science. These scholars include physicians and Ph.D. scientists who are generally assistant professors in clinical departments. This...

Cite
Meagher E, Taylor L, Probsfield J, et al. Evaluating research mentors working in the area of clinical translational science: a review of the literature. Clin Transl Sci. 2011;4(5):353-8doi: 10.1111/j.1752-8062.2011.00317.x.
Meagher, E., Taylor, L., Probsfield, J., & Fleming, M. (2011). Evaluating research mentors working in the area of clinical translational science: a review of the literature. Clinical and translational science, 4(5), 353-8. https://doi.org/10.1111/j.1752-8062.2011.00317.x
Meagher, Emma, et al. "Evaluating research mentors working in the area of clinical translational science: a review of the literature." Clinical and translational science vol. 4,5 (2011): 353-8. doi: https://doi.org/10.1111/j.1752-8062.2011.00317.x
Meagher E, Taylor L, Probsfield J, Fleming M. Evaluating research mentors working in the area of clinical translational science: a review of the literature. Clin Transl Sci. 2011 Oct;4(5):353-8. doi: 10.1111/j.1752-8062.2011.00317.x. PMID: 22029808; PMCID: PMC3727275.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries